about
Antibody responses to envelope glycoproteins in HIV-1 infectionAntibodies in HIV-1 vaccine development and therapyThe role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaquesLive attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaquesVaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protectionA novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitroInternational network for comparison of HIV neutralization assays: the NeutNet report IIPassive immunization against HIV/AIDS by antibody gene transfer.Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination StrategiesWhich Antibody Functions are Important for an HIV Vaccine?Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses.Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphismHIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells.New paradigms for functional HIV-specific nonneutralizing antibodiesHIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfectionCharacterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infectionRationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Receptor binding domain based HIV vaccines.Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeysShort communication: Fc gamma receptors IIa and IIIa genetic polymorphisms do not predict HIV-1 disease progression in Kenyan women.Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.No acquisition: a new ambition for HIV vaccine development?Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport.A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens.Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs.Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection.The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variantImproving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formationInduction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinantsA nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.A mouse model for HIV-1 entryStrategies for eliciting HIV-1 inhibitory antibodiesVirus-specific antibodies allow viral replication in the marginal zone, thereby promoting CD8(+) T-cell priming and viral controlNeutralizing antibodies to HIV-1 induced by immunization.Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicidesFc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment.
P2860
Q26991572-42C2B31A-786D-4098-9E53-2E5E8BC107C1Q27011574-FDCA0AD8-FDF8-4AD6-9611-86120A2CA659Q27305204-25E87FB4-878C-4DCE-A7BC-8CD9310E7982Q27305234-FAEE2D71-A6FC-41F7-BFEA-0E237B55B5F5Q27332360-28A94878-3244-4803-BBB7-FF143D464902Q28728917-C3C2CFF9-EEAC-4043-9AA7-D280D76C977BQ28730045-9B1C8FB6-E564-47D8-AD2F-F1F39D07495DQ30358434-E9F642C0-948F-4C19-B8B7-B507FA90955EQ30408097-E7111E11-B940-4F22-A206-D87E446AB1B5Q33772637-C4630E5A-419F-4EC1-A2A8-68F9AF12EBACQ33842408-5A1208CD-3B84-4641-974E-7B4316E86A0AQ33880717-0994BF1B-9B23-4937-AF50-E4585B70BF08Q33887674-2EE33347-FB98-4AC2-B1B6-2CCDEA2F289BQ33900595-DCF76F4E-9535-4FF6-A649-93AADE9B288CQ33947008-90A5F7EF-ABFC-424D-8163-93ECE99B96EDQ33966586-700CEF6B-6104-486E-B7AE-0DF2CA2B20F9Q34016675-BA66C1B4-7FCD-4BDF-93FF-82599B7F0B27Q34300812-AA2E1FBB-BE1A-4F71-A833-9710B8CE21E9Q34540352-3397B502-F5C5-4A6A-9939-E0266682ACA7Q35033862-2DA69630-6502-43C3-93F8-CB1F84F188B7Q35076987-1680C034-B938-4250-91DC-4E61F3817397Q35077438-511DB949-FA5F-41D3-9604-7EF16D0D886CQ35077793-6BDEB5DE-F250-47EF-B2DF-DE6996B047EDQ35142518-5E23FDC5-3FB9-4062-95D0-9E5A5EE674BBQ35160124-C979CE81-C3D9-4B86-A313-E94C6ECCF633Q35534563-755472F7-5765-4416-B0DC-396D6DEBB1DFQ35546930-B88ABACD-96CF-4DBD-8519-7FBE63FD1A23Q35566508-8F027FC4-1EA8-4283-B1CF-2DBE4F7A8AC5Q35824686-2DCCF9B7-27E1-4E31-B3C3-E2D5F29A7C6DQ35826668-8749A72A-C0E1-46EC-BD26-5063971274AAQ35876561-0B24BDE6-99C8-48EA-9552-11B0BD646AA2Q35893538-835012A2-D069-4414-9201-C0FEA7CDE05DQ35973518-4978A976-765B-460F-926B-397FDDEE9BB6Q36023146-10666404-D2DF-446E-BFC5-9277B4EB95D4Q36300767-7256366D-8369-45B4-92A8-ABA64BC8600BQ36452155-19F85C3A-3327-435F-993C-65018790141BQ36501145-BD6CC79D-6791-4DB7-8875-559B8FF96FC8Q36603515-FB94BB68-A133-40EF-A8CB-E39C44115875Q36785795-74D9124E-6A69-41F6-961A-FC4C233E1BBCQ37152107-FEA26A87-B753-4BED-955B-53A4A7901690
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Fc receptor-mediated antiviral antibodies.
@ast
Fc receptor-mediated antiviral antibodies.
@en
type
label
Fc receptor-mediated antiviral antibodies.
@ast
Fc receptor-mediated antiviral antibodies.
@en
prefLabel
Fc receptor-mediated antiviral antibodies.
@ast
Fc receptor-mediated antiviral antibodies.
@en
P2860
P1476
Fc receptor-mediated antiviral antibodies.
@en
P2093
Christiane Moog
Donald N Forthal
P2860
P304
P356
10.1097/COH.0B013E32832F0A89
P577
2009-09-01T00:00:00Z